A new erectile dysfunction drug, which is currently being tested by its developer, Vivus, is said to be highly efficient, fast to take effect and, thus, being a potential rival to Viagra and Cialis.
On Monday, November 14th, Vivus announced that its erectile dysfunction drug Avanfil, which is currently being investigated, acts in as little as it minutes. The proportion of men, in whom the drug was successful, reached 83%. The data was presented at the Sexual Medicine Society of North America in Las Vegas, Nevada.
Commenting on he findings of the clinical trials, one of men’s healthcare professionals said: “Based on the results of the study, this onset of action suggests that avanafil, if approved, is potentially well-suited for on-demand treatment in men with mild to severe erectile dysfunction.”
The news caused an immediate reaction from investors, who have started buying Vivus shares. On Monday afternoon, the price of Vivus shares went up by 1.61% and reached $10.08 per share.
Vivus is to apply for the approval by the US Food and Drug Administration as it completes the trials of Avanfil.









